Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:FSDDFOTCMKTS:IGXTNASDAQ:IVVDNASDAQ:KRRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFSDDFFSD Pharma$15.37+5.6%$9.49$3.43▼$68.66$116.51MN/A11,100 shs217,906 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AIVVDInvivyd$0.85-2.6%$0.70$0.35▼$2.74$101.58M0.634.53 million shs911,289 shsKRROKorro Bio$13.98-6.0%$14.66$10.29▼$98.00$139.64M2.45110,757 shs72,676 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFSDDFFSD Pharma-4.34%-5.86%+60.33%+216.99%+5,937.34%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%IVVDInvivyd-4.03%-10.33%+3.72%+7.01%-46.36%KRROKorro Bio-6.18%+25.17%-6.95%-39.70%-64.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFSDDFFSD PharmaN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AIVVDInvivyd3.8185 of 5 stars3.64.00.00.02.73.31.3KRROKorro Bio3.5719 of 5 stars4.63.00.00.04.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFSDDFFSD Pharma 0.00N/AN/AN/AIGXTIntelGenx Technologies 0.00N/AN/AN/AIVVDInvivyd 3.25Buy$5.85590.84% UpsideKRROKorro Bio 3.29Buy$102.43632.68% UpsideCurrent Analyst Ratings BreakdownLatest IGXT, IVVD, FSDDF, and KRRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $5.005/16/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.005/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.005/8/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$115.00 ➝ $100.004/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/20/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/20/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFSDDFFSD Pharma$70K1,664.35N/AN/AN/A∞IGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39IVVDInvivyd$36.69M2.77N/AN/A$1.61 per share0.53KRROKorro Bio$4.82M27.23N/AN/A$21.19 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFSDDFFSD Pharma-$17.52MN/A0.00∞N/AN/AN/AN/AN/AIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/AIVVDInvivyd-$198.64M-$1.20N/A7.70N/AN/A-155.33%-114.88%8/13/2025 (Estimated)KRROKorro Bio-$81.17M-$9.44N/AN/AN/AN/A-50.25%-38.48%8/12/2025 (Estimated)Latest IGXT, IVVD, FSDDF, and KRRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IVVDInvivyd-$0.04-$0.14-$0.10-$0.14$34.45 million$11.30 million5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million3/20/2025Q4 2024IVVDInvivyd-$0.25-$0.15+$0.10-$0.15$13.57 million$13.80 million3/18/2025Q4 2024KRROKorro Bio-$2.33-$2.26+$0.07-$2.26N/A$2.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFSDDFFSD PharmaN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFSDDFFSD PharmaN/A1.811.60IGXTIntelGenx TechnologiesN/AN/AN/AIVVDInvivydN/A1.921.58KRROKorro BioN/A11.2311.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFSDDFFSD Pharma0.43%IGXTIntelGenx TechnologiesN/AIVVDInvivyd70.36%KRROKorro Bio13.18%Insider OwnershipCompanyInsider OwnershipFSDDFFSD PharmaN/AIGXTIntelGenx Technologies42.05%IVVDInvivyd25.40%KRROKorro Bio4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFSDDFFSD Pharma107.58 millionN/ANot OptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableIVVDInvivyd100119.96 million98.21 millionOptionableKRROKorro Bio709.39 million8.86 millionNo DataIGXT, IVVD, FSDDF, and KRRO HeadlinesRecent News About These CompaniesCantor Fitzgerald Estimates Korro Bio FY2026 EarningsJune 12 at 3:21 AM | americanbankingnews.comCantor Fitzgerald Predicts Korro Bio FY2026 EarningsJune 10 at 8:56 AM | marketbeat.comKorro Bio, Inc. (NASDAQ:KRRO) Receives $102.43 Average Target Price from AnalystsJune 6, 2025 | americanbankingnews.comKorro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of "Buy" from AnalystsJune 3, 2025 | marketbeat.comMillennium Management LLC Has $3.65 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO)June 1, 2025 | marketbeat.comWoodline Partners LP Invests $3.89 Million in Korro Bio, Inc. (NASDAQ:KRRO)May 27, 2025 | marketbeat.comBrokers Offer Predictions for Korro Bio FY2025 EarningsMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Increases Stake in Korro Bio, Inc. (NASDAQ:KRRO)May 20, 2025 | marketbeat.com75,000 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Polar Capital Holdings PlcMay 19, 2025 | marketbeat.comOrbimed Advisors LLC Acquires New Holdings in Korro Bio, Inc. (NASDAQ:KRRO)May 15, 2025 | marketbeat.comCitadel Advisors LLC Sells 159,440 Shares of Korro Bio, Inc. (NASDAQ:KRRO)May 15, 2025 | marketbeat.comKorro to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)May 14, 2025 | theglobeandmail.comKorro Bio FY2025 EPS Estimate Raised by Cantor FitzgeraldMay 13, 2025 | marketbeat.comQ2 Earnings Forecast for Korro Bio Issued By HC WainwrightMay 13, 2025 | marketbeat.comQ2 Earnings Estimate for Korro Bio Issued By William BlairMay 13, 2025 | marketbeat.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of Korro Bio (KRRO) with Overweight RecommendationApril 30, 2025 | msn.comChardan Capital Initiates a Buy Rating on Korro Bio (KRRO)April 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGXT, IVVD, FSDDF, and KRRO Company DescriptionsFSD Pharma OTCMKTS:FSDDF$15.37 +0.82 (+5.64%) As of 06/11/2025FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Invivyd NASDAQ:IVVD$0.85 -0.02 (-2.55%) As of 04:00 PM EasternInvivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Korro Bio NASDAQ:KRRO$13.98 -0.89 (-5.99%) As of 04:00 PM EasternKorro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
